MedTrace Logo

SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

NCT06442280 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 544

Last updated 2024-06-06

No results posted yet for this study

Summary

The purpose of the current investigation is to demonstrate the efficacy of high-dose furosemide plus small-volume hypertonic saline solution and a Sodium-Glucose cotransporter-2 (SGLT-2) inhibitor among patients admitted for acute exacerbation of heart failure, in determining a significant increase in diuresis and natriuresis. It is also accompanied by a rapid reduction in body weight and a substantial decrease in hospitalization length without compromising renal function.

Conditions

Interventions

DRUG

Dapagliflozin tablet

Dapagliflozin 10 mg 1 tablet once daily

DRUG

Hypertonic Saline Solution, 1 Ml

Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily

DRUG

Furosemide Injection

Furosemide 20 mg

Sponsors & Collaborators

  • University of Palermo

    lead OTHER

Principal Investigators

  • Giuseppe Miceli, PhD · A.O.U.P. Paolo Giaccone Palermo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2026-01-31
Completion
2026-03-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06442280 on ClinicalTrials.gov